Skip to main content
Smart Investors Daily
Intuitive Surgical, Inc. logo

NASDAQ · ISRG

Intuitive Surgical, Inc.

Healthcare · Medical - Instruments & Supplies

$407.24

Down-$13.71 (-3.26%)

Updated Nov 20, 2026, 2:12 AM

SID Score

4.7/10

Composite research score

Smart Money

40/100

Neutral

Market cap
195.51B
P/E ratio
71.05
Dividend yield
0.00%
52-week range
$328.57 – $553.74
Volume
2.09M
Avg. volume
2.26M

Price performance · ISRG

ISRG price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

ISRG closed at $407.24 after 21 trading sessions, down 8.25% for the selected period.

Last close
$407.24
Period change
-8.25%
Period low
$407.24
Period high
$482.10
Daily close
View OHLC price history
ISRG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$421.45$425.105$404.85$407.242.09M
Nov 18, 2026$430.20$437.325$420.84$420.952.22M
Nov 17, 2026$437.33$441.285$428.71$430.532.53M
Nov 16, 2026$444.38$446.20$436.71$437.751.82M
Nov 13, 2026$443.69$448.85$441.00$443.591.6M
Nov 12, 2026$449.00$451.26$438.44$439.891.79M
Nov 11, 2026$446.00$451.00$443.24$449.531.75M
Nov 10, 2026$460.48$460.48$444.16$450.041.66M
Nov 9, 2026$456.66$463.00$454.04$460.562.16M
Nov 6, 2026$457.00$463.25$450.5125$452.802.15M
Nov 5, 2026$482.88$485.17$461.19$468.524.7M
Nov 4, 2026$458.99$485.85$453.69$482.104.83M
Nov 3, 2026$436.65$443.58$434.05$440.751.74M
Nov 2, 2026$439.79$446.455$436.04$436.873.81M
Oct 30, 2026$453.60$453.60$431.1949$432.013.48M
Oct 29, 2026$447.85$450.40$443.475$448.761.89M
Oct 28, 2026$441.425$449.97$437.5101$444.181.85M
Oct 27, 2026$451.63$451.63$443.8501$445.881.7M
Oct 26, 2026$451.93$458.88$447.61$451.633.07M
Oct 23, 2026$443.65$458.45$442.56$452.293.01M
Oct 22, 2026$430.745$444.15$427.47$443.852.78M

Latest ISRG news

The latest Smart Investors Daily articles mentioning ISRG.

ISRG research

Overview

Company profile and research snapshot.

Company profile

Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$618.00
Implied upside
—
Analysts
23
ISRG recent ratings
DateFirmRatingTarget
Nov 18, 2026BTIGBuy—
Oct 21, 2026Evercore ISI GroupIn-Line—
Oct 21, 2026BarclaysOverweight—
Oct 21, 2026TD CowenBuy—
Oct 21, 2026Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

Intuitive Surgical Stock Performance

Intuitive Surgical, Inc. shares closed at $420.95, declining 0.85% in the most recent session, per SID market data. The stock has exhibited mixed momentum across timeframes, posting a modest 1-month decline of 0.61% while gaining 8.25% over the trailing three months. On a 12-month basis, however, ISRG has retreated 21.26%, reflecting broader pressure on high-multiple healthcare names. The stock currently trades just above its 50-day moving average of $420.62 but remains below its 200-day moving average of $429.00, indicating a neutral-to-bearish technical posture. The 14-day relative strength index stands at 45.3, placing the stock in neutral territory without overbought or oversold signals. ISRG carries a beta of 1.686, per Massive/Polygon data, indicating significantly higher volatility relative to the broader market. Average daily trading volume stands at approximately 2.26 million shares, supporting adequate liquidity for institutional participants.

Intuitive Surgical Valuation Analysis

Intuitive Surgical commands a market capitalization of approximately $195.5 billion, reflecting its dominant position in robotic-assisted surgery, per SID market data. The company's trailing price-to-earnings ratio stands at 71.05, well above the broader healthcare sector average, underscoring the premium valuation investors assign to its growth trajectory and competitive moat. The PEG ratio of 13.30 suggests that even when adjusting for expected earnings growth, the stock trades at an elevated multiple relative to typical growth benchmarks. According to SEC filings, the price-to-book ratio registers at 11.53, further highlighting the significant premium over tangible asset value. Intuitive Surgical pays no dividend, consistent with its reinvestment-focused capital allocation strategy. As a healthcare sector constituent with no yield component, the stock's investment case rests entirely on capital appreciation driven by procedure volume growth, system placements, and recurring instrument and accessory revenue streams.

Smart Money Activity for ISRG

Intuitive Surgical's composite smart money score stands at 40 out of 100, registering a neutral signal, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, reflecting strong conviction among large asset managers and mutual funds in the company's long-term positioning. In contrast, the insider sentiment component scores just 5.3 out of 25, weighed down by a notable imbalance in recent insider transactions. According to SEC Form 4 filings, there have been 20 insider trades over the past 90 days, comprising 6 purchases and 14 sales, indicating that company insiders have been net sellers during this period. Dark pool activity scores 8.5 out of 25, suggesting moderate but not elevated institutional block trading. Congressional trading activity is minimal, registering only 0.8 out of 25 per 13F institutional filings. The divergence between strong institutional ownership and insider selling patterns presents a nuanced signal, with institutional holders maintaining positions while insiders reduce exposure at current valuation levels.

Intuitive Surgical Earnings Outlook

Intuitive Surgical has demonstrated a consistent pattern of exceeding analyst expectations across its three most recent reported quarters, according to company earnings reports. In the most recent quarter, the company delivered earnings per share of $3.00 against a consensus estimate of $2.54, representing an 18.1% upside surprise. The prior quarter showed EPS of $2.80 versus the $2.41 estimate, a $0.39 positive surprise, while the quarter before that produced EPS of $2.50 compared to the $1.92 consensus, delivering the largest beat of $0.58 or 30.2% above expectations. Analyst estimates for the upcoming quarter project EPS of $2.41, per consensus data. The sequential acceleration in absolute earnings from $2.50 to $2.80 to $3.00 reflects robust underlying business momentum driven by increasing da Vinci system utilization and growing procedure volumes. The consistent pattern of outperformance suggests that analyst models may continue to underestimate the company's earnings power.

Wall Street Analyst Ratings for ISRG

Wall Street consensus on Intuitive Surgical remains predominantly bullish, with four of the five most recent analyst actions carrying positive ratings, per Wall Street analyst reports. BTIG reiterated a Buy rating on November 18, 2026, maintaining its constructive stance on the stock. Following the company's earnings release on October 21, 2026, multiple firms reaffirmed their positive outlooks: Barclays maintained an Overweight rating, Wells Fargo reiterated Overweight, and TD Cowen held its Buy recommendation. Evercore ISI Group maintained its In-Line rating, representing the sole neutral voice among recent coverage updates, per SID consensus data. Notably, none of the five most recent analyst actions involved a rating change, with each firm reiterating its prior assessment, suggesting stable institutional conviction despite the stock's 21.26% year-over-year decline. The absence of any downgrades following earnings results indicates that the company's fundamental performance continues to meet or exceed the investment theses underpinning these bullish recommendations from major sell-side firms.